Seres Therapeutics MCRB 深 滬
等待開盤 11-04 09:30:00 美东时间
1.96
+0.130
+7.10%
華盛通- 最 高1.98
- 今 開1.97
- 成交量 5.31万股
- 最 低 1.85
- 昨 收 1.83
- 總市值 1968.78万
- 52周最高 29.98
- 市盈率 靜 3.05
- 換手率 0.53%
- 52周最低 1.675
- 委 比 -54.74%
- 總股本 1004.48万
- 歷史最高 1040.00
- 量 比 0.54
- 振 幅 7.10%
- 歷史最低 1.675
- 每 手 1
- 風險率 4.93%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Seres Therapeutics Announces Publication of SER-155 Phase 1b Results in Nature Medicine Showing Reduced Bloodstream Infections in Allogeneic Hematopoietic Cell Transplantation Recipients
Seres Therapeutics' SER-155, an investigational live biotherapeutic, demonstrated a 77% relative risk reduction in bloodstream infections (BSIs) and significantly lower systemic antibiotic exposure compared to placebo in a Phase 1b clinical study published in *Nature Medicine*. The study involved adults undergoing allogeneic hematopoietic cell transplantation (allo-HCT). SER-155 was well-tolerated, with no treatment-related serious adverse events...
11-03 12:00
Seres Therapeutics收涨3.39%，成交额8.43万美元
11月3日，Seres Therapeutics（MCRB）收涨3.39%，报1.83美元，成交额8.43万美元，市值1838.19万美元。 行情数据 • 开盘...
11-03 08:47
Seres Therapeutics收跌5.26%，成交额10.84万美元
10月27日，Seres Therapeutics（MCRB）收跌5.26%，报1.98美元，成交额10.84万美元，市值1988.87万美元。 行情数据 •...
10-27 07:47
Seres Therapeutics Announces Upcoming CFO Leadership Transition
Seres Therapeutics ( ($MCRB) ) has shared an update. On October 22, 2026, Seres...
10-27 05:01
On, October 22, 2026, Seres Therapeutics' CFO Marella Thorell Resigned Effective November 15, 2026
On October 22, 2026, Marella Thorell, Executive Vice President and Chief Financial Officer of Seres Therapeutics, Inc. (the "Company"), resigned from her positions as Executive Vice President and Chief Financial Officer of the Company, effective November 15, 2026 (the "Effective Date"). Following th...
10-27 04:52
Seres Therapeutics收跌2.77%，成交额9.6万美元
10月20-22日上海黄浦江畔，2026可持续全球领导者大会再度来袭。诺奖、图灵奖得主现场讲述科技未来与趋势，更有“解救”焦虑、内卷时代的网红教授——麦克法兰与...
10-17 07:47
Seres Therapeutics To Present Preclinical Data Supporting Development Of SER-428, Investigational Oral Liquid LBP To Reduce Risk Of Bloodstream Infections In Critically Ill Patients, At IDWeek 2026
Novel oral liquid formulation of SER-428 is designed for patients who cannot take oral capsules, including critically ill patients receiving nutrition via feeding tube SER-428 significantly reduced gastrointestinal abundance of clinically relevant pathogens in preclinical in vivo colonization models...
10-15 19:07
Seres Therapeutics to Present Preclinical Data for SER-428, an Investigational Live Biotherapeutic Designed to Reduce Risk of Bloodstream Infections in Critically Ill Patients, at IDWeek 2026
Seres Therapeutics announced preclinical data for SER-428, an investigational oral liquid live biotherapeutic product (LBP) designed to reduce bloodstream infections (BSIs) in high-risk patients after sepsis and antibiotic exposure. The novel liquid formulation enables dosing for patients unable to take oral capsules, including critically ill patients receiving nutrition via feeding tube. In preclinical models, SER-428 significantly reduced gastr...
10-15 11:00
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Seres Therapeutics granted stock options to purchase 4,200 shares of common stock to two new employees under its 2022 Inducement Plan. The options have an exercise price of $5.72 per share, vesting 25% after one year and 6.25% every three months thereafter. The company focuses on developing live biotherapeutics to address unmet needs in oncology and inflammatory diseases. For more information, visit www.serestherapeutics.com.
09-08 22:00
Seres Therapeutics Files Prospectus for Up To $300M Offering Of Common Stock, Preferred Stock, Debt, Warrants And Units
SERES THERAPEUTICS, INC. $300,000,000 Common Stock Preferred Stock Debt Securities Warrants Units We may offer and sell up to $300,000,000 in the aggregate of the securities identified above from time to time in one or more offerings. This prospectus provides you with a general description of the se...
08-14 05:21
